Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone.

ABSTRACT:

Purpose

After failing primary and secondary hormonal therapy, castration-resistant and neuroendocrine prostate cancer metastatic to the bone is invariably lethal, although treatment with docetaxel and carboplatin can modestly improve survival. Therefore, agents targeting biologically relevant pathways in prostate cancer and potentially synergizing with docetaxel and carboplatin in inhibiting bone metastasis growth are urgently needed.

Experimental design

Phosphorylated (activated) AXL expression in human prostate cancer bone metastases was assessed by IHC staining. We evaluated the effects of a novel soluble AXL signaling inhibitor, sAXL (batiraxcept or AVB-S6-500), on tumor growth and lung metastases in prostate cancer patient-derived xenograft models that were implanted in

SUBMITTER: Chiu CL 

PROVIDER: S-EPMC11961319 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature